News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Cintas (NasdaqGS: CTAS) has separated the President and CEO roles, with Jim Rozakis appointed President and COO while Todd Schneider remains CEO. The …
Sharemaestro market context Price above Trend Line 52 weeks -9.5% · Next-week setup negative 32.9%Editas Medicine (EDIT) saw its stock rally by about 5% after reporting Q2 2026 earnings, driven by a significant increase in revenue to US$11.89 million from US$3.58 million year-on-year. While the company is still reporting losses, these narrowed to US$18.23 million from US$53.24 million, …
This article from TradingKey provides current stock information for Datasea Inc (DTSS). It details the stock's closing price, market capitalization, and indicates that more news, earnings reports, analyst ratings, and key developments will be available soon.
Ventas Inc. (VEN) reported its Q2 2023 earnings, beating analyst expectations for both EPS and revenue. The company announced an actual EPS of CHF0.21 against a consensus of CHF0.02, and actual revenue of CHF893.96M compared to an expected CHF881.06M, marking an 8.15% year-over-year revenue …
After reaching an important support level, Cintas (CTAS) could be a good stock pick from a technical perspective. CTAS surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a well-liked trading tool because it provides …
Sharemaestro market context Price above Trend Line 52 weeks -9.5% · Next-week setup negative 32.9%Assenagon Asset Management S.A. significantly increased its stake in Cintas Corporation, now holding 1.22 million shares valued at $207.09 million. Cintas continues to impress with strong earnings and revenue growth, beating analyst expectations and increasing its quarterly dividend. The company maintains a "Moderate Buy" …
Navitas Semiconductor (NVTS) stock surged over 9% following better-than-expected Q3 revenue guidance and a strategic pivot towards high-power GaN and SiC markets driven by AI data centers. The "Navitas 2.0" plan focuses on high-value AI infrastructure, which is projected to exceed one-third of sales …
Cintas Corp (CTAS) has healthy fundamentals and high growth potential, with its valuation considered fairly valued within the Professional & Commercial Services industry. The stock has high institutional ownership and analysts rate it as a "Buy," with expectations for an upward trend in the …
TaskUs (TASK) stock surged 24% following a strong Q2 2026 earnings report, driven by growth in its AI Services revenue and robust cash flow generation. The company's adjusted EBITDA margin reached 18.7%, and it raised its full-year cash guidance, signaling a successful pivot towards …
Analysts have issued a consensus "Hold" rating for Navitas Semiconductor (NASDAQ:NVTS), with an average 12-month price target of $15.92. The company recently reported quarterly revenue of $10.53 million, beating estimates, while adjusted EPS of ($0.04) met expectations, though revenue was down 27.3% year over …
Navitas Semiconductor is disputing patent infringement allegations filed by Wolfspeed in a Delaware District Court. Navitas, which manufactures gallium nitride and silicon carbide power semiconductors, stated it would defend itself against what it characterized as baseless accusations, asserting its technology is a result of …
Navitas Semiconductor (NVTS) stock rose over 20% after the company announced its new 800 V-to-6 V DC-DC power chip is being showcased in Nvidia’s MGX Ecosystem at Computex 2026. This collaboration aims to help data centers consume electricity more efficiently and address the high …
Editas Medicine (EDIT) reported a narrower-than-expected loss of 15 cents per share in Q2 2026, with revenues significantly surpassing estimates at $11.9 million due to deferred revenues. The company's lead gene-editing candidate, EDIT-401, for heterozygous familial hypercholesterolemia, showed encouraging preclinical data with rapid and …
Editas Medicine, Inc. reported an increase in collaboration and research revenue to $11.89M for the quarter ended 2026, with a reduced net loss of ($18.23M) and improved diluted EPS of ($0.15). Key highlights include the nomination of EDIT-401 as the lead in vivo candidate …
This article provides an earnings forecast for Datasea Inc (DTSS), including future EPS and revenue growth estimates. It notes that the company's stock is currently trading at $0.785 and lists its market capitalization. The article also presents a peer comparison with other companies in …
For most investors, how much a stock's price changes over time is important. This factor can impact your investment portfolio as well as help you compare investment results across sectors and industries. The fear of missing out, or FOMO, also plays a factor in …
Sharemaestro market context Price above Trend Line 52 weeks -9.5% · Next-week setup negative 32.9%Janus Henderson Group PLC increased its stake in Cintas Corporation (NASDAQ:CTAS) by 20% in the first quarter, acquiring an additional 8,623 shares, bringing their total holdings to 51,716 shares valued at $8.75 million. Cintas has consistently exceeded quarterly expectations, reporting strong revenue growth and …
Pacer Advisors Inc. significantly reduced its stake in Cintas Corporation (NASDAQ:CTAS) by 34.8% in the first quarter, selling over 21,000 shares. Despite this, Cintas continues to exceed earnings expectations, reporting $1.29 EPS and $2.91 billion in revenue, and has increased its quarterly dividend. The …
Bank of New York Mellon Corp increased its stake in Navitas Semiconductor Corporation (NVTS) by 21.8% in the first quarter, now holding 566,465 shares valued at $4.97 million. Institutional investors collectively own 46.14% of NVTS, while analysts maintain a "Hold" rating with a consensus …
Intrepid Potash (IPI) stock, trading at a P/E of 28.5x, saw a slight share price slip despite improved gross margins and adjusted EBITDA in Q2 2026. While operational efficiencies and higher realized prices for TRIO and potash supported a bullish outlook, net income from …
Key Points Interested in Intrepid Potash, Inc? Here are five stocks we like better. Profitability improved in Q2: Adjusted EBITDA rose to $17.5 million from $13.8 million, while gross margin increased 35% to $16.6 million, driven by stronger Trio margins and improved potash operations. …
Editas Medicine (NASDAQ: EDIT) announced its second quarter 2026 financial results and provided business updates. The company highlighted recent progress in its CRISPR-based therapeutic programs and discussed its financial position, offering insights into its strategic direction and upcoming milestones for the remainder of the …
Editas Medicine (NASDAQ:EDIT) announced its quarterly earnings, reporting an adjusted loss of $0.15 per share, surpassing the consensus estimate of a $0.27 loss, with revenue of $11.89 million, significantly exceeding analyst expectations of $2.85 million. Despite beating revenue and EPS estimates, the company remains …
Search by ticker symbol or company name and select a result to open its chart.